E. Maartense

Leiden University Medical Center — Netherlands

Medicine · Health Sciences

20h-index3.3kcitations58works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(11), Estrogen and related hormone effects(11), Breast Cancer Treatment Studies(10), Cancer Treatment and Pharmacology(8), HER2/EGFR in Cancer Research(6)

Publications58 total

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
JNCI Journal of the National Cancer Institute·2017· 196 citedOpen Access
Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Data Archiving and Networked Services (DANS)·2017· 1 cited
Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Cancer Research·2017
Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Cancer Research·2017· 20 cited
Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)
European Journal of Cancer·2017· 12 cited
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study
Journal of Clinical Oncology·2015· 660 cited
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
Breast Cancer Research and Treatment·2015· 58 citedOpen Access
Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study
Annals of Hematology·2015· 18 citedOpen Access
Three components of a geriatric screening determine the geriatric prognostic index (GPI) as risk profile before chemotherapy in the elderly
Journal of Geriatric Oncology·2014
Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
Annals of Oncology·2014· 3 citedOpen Access
Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists.
PubMed·2014· 14 cited
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
Annals of Oncology·2014· 38 citedOpen Access
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
Annals of Oncology·2014· 60 citedOpen Access
Abstract P1-08-19: Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): A Dutch breast cancer trialists group (BOOG) side-study
Cancer Research·2013· 1 cited
Abstract P1-06-04: The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists’ group (BOOG) side-study
Cancer Research·2013· 1 cited
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
The Breast·2013· 133 cited
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
Journal of Clinical Oncology·2013
NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)—A Dutch Breast Cancer Trialists’ Group (BOOG) study.
Journal of Clinical Oncology·2013· 7 cited
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
Journal of Clinical Oncology·2013· 22 cited
The insulin-like growth factor-system in a patient with diffuse large B-cell non-Hodgkin's lymphoma and lactic acidosis
Annals of Clinical Biochemistry International Journal of Laboratory Medicine·2013· 9 cited
page 1 of 3Next →

Frequent Co-authors

Hein Putter(13), J.W.R. Nortier(11), Gerrit‐Jan Liefers(9), Judith R. Kroep(8), Elma Meershoek‐Klein Kranenbarg(7), Caroline Seynaeve(7), A. Elise van Leeuwen‐Stok(6), Carolien H. Smorenburg(6), Felix E. de Jongh(5), Emiel J. Rutgers(5), Cornelis J.�H. van de Velde(5), Saskia le Cessie(5), Marije E. Hamaker(5), Harm van Tinteren(5), Hanneke C. Kluin‐Nelemans(5), H. de Graaf(4), Simone Snijder(4), P. W. Wijermans(4), Vincent T.H.B.M. Smit(4), Marcus Schmidt(3)